Artemis Medicare Q1 FY27 Earnings Call — Analysis (NSE: ARTEMISMED)
Artemis reports strong Q1 FY27 with 12.7% revenue growth, 21.5% EBITDA margin, and 48.3% PAT jump; commences Raipur operations and unveils 200+ bed Tower IV for advanced pediatric quaternary care.
Result quality: stable — Steady quarter. Management sentiment: optimistic.
The take
Q1FY27 Revenue ₹287.32 Cr ( +12.7% YoY ) . New guidance — Q2FY27 international patient revenue s… closer to, if not better than 30% . New story: Brownfield capacity build-out and Tower IV .
Results
Revenue ₹287.32 Cr (+12.7% YoY); EBITDA margin 21.5%; PAT ₹31.44 Cr (+48.3% YoY).
Financial highlights
| Metric | Value | Change | Basis |
|---|---|---|---|
| Revenue | ₹287.32 Cr | +12.7% | yoy · Q1FY27 |
| EBITDA | ₹61.82 Cr | none · Q1FY27 | |
| EBITDA Margin | 21.5% | none · Q1FY27 | |
| PAT | ₹31.44 Cr | +48.3% | yoy · Q1FY27 |
| Occupancy (Gurgaon) | 65.7% | point_in_time · Q1FY27 · as of Jun-26 | |
| ARPOB (Gurgaon) | ₹85,690 | none · Q1FY27 |
Guidance
Raipur hospital to break even in 15–18 months with ~₹20 Cr total operating loss; Tower IV Gurgaon (₹120 Cr, 200+ beds) to be operational in 18–22 months; FY27–29 cumulative capex pegged at ~₹800 Cr.
What management committed to
- International patient revenue share will be closer to, if not better than, 30% in Q2 FY27. — closer to, if not better than 30%, Q2FY27
- Raipur hospital will break even within 15 to 18 months of commencement (July 2026), with total operating loss not exceeding approximately ₹20 Cr. — around 15 to 18 months of break-even, around INR 20 crores of overall operating loss, Q3FY28
- Gurgaon flagship hospital occupancy will reach 70% by Q2 FY27. — 70%, Q2FY27
- Tower IV at Gurgaon (200+ beds) will be fully operational within 18 to 22 months from August 2026. — between 18 to 22 months, Q2FY28
- Tower IV capex will be approximately ₹120 Cr, at a per-bed cost of ₹55 lakhs. — INR 55 lakhs per bed, overall INR 120 crores
- Cumulative capex for FY27, FY28 and FY29 will be close to ₹800 Cr, covering Raipur, VIMHANS, Tower IV and replacement capex. — close to INR 800 crores, FY29
- Standalone Gurgaon hospital EBITDA margin will be 20–21% in FY27. — 20% to 21%, FY27
- Gurgaon hospital EBITDA margin will scale to 23–24% over the next 2–3 years. — 23%-24%, FY29-FY30
- Raipur hospital will obtain direct insurance empanelment within 8–10 weeks from the call date (early Aug 2026). — 8 to 10 weeks, Q2FY27
- The full deposit of ₹250 Cr for VIMHANS will be paid by end of FY27; remaining ~₹120 Cr to be funded from existing IFC proceeds within the current financial year. — remaining INR 120 crores to be paid by end FY27, FY27
- The company will raise up to ₹700 Cr via QIP for brownfield acquisitions with EBITDA-positive assets; the raise will be launched 6–8 months after asset finalization, with minimal dilution. — INR 700 crores enabling resolution, FY28
Key themes
Brownfield expansion, margin optimization, and quaternary care differentiation
How the narrative shifted
- Brownfield capacity build-out and Tower IV: Management presents Tower IV as a high-ROIC, low-risk expansion to pre-empt capacity constraints and elevate pediatric quaternary care positioning, leveraging existing infrastructure and clinical teams.
- Margin expansion through scale and case mix: Rising ARPOB and occupancy are driving operating leverage; management attributes Q1 margin improvement to economies of scale, better case mix, and cost efficiencies, and commits to further margin uplift.
- Geographic diversification beyond NCR: Raipur launch and planned South Delhi facility are framed as de-risking moves, extending the Artemis brand into central and southern Delhi while targeting underserved tertiary markets.
- Pediatric and OB quaternary care as a differentiator: Tower IV is explicitly positioned to showcase Artemis’s advanced pediatric and women’s care capabilities, aiming to become the nodal referral centre for Haryana/NCR and out-compete standalone pediatric chains.
- International patient resilience and diversification: Despite the West Asian conflict, international revenues held at 27% due to multi-region sourcing; management expects a bounce to 30% in Q2, underscoring the durability of the medical value travel platform.
- Capital discipline and QIP enabler: Management emphasises that the ₹700 Cr QIP is an enabling resolution; actual raise will be calibrated to asset quality, keeping dilution minimal, while internal accruals fund announced projects.
Operational commentary
- Artemis Shanti Hospital, Raipur (300-bed) commenced operations — OPD from 9th July, OT/cath lab from 27th July; full range of specialties including oncology, neurosurgery, and advanced cardiac care started simultaneously; PET-CT under installation, radiotherapy unit expected soon; initial OPD footfalls and early complex surgeries encouraging.
- Tower IV at Gurgaon campus announced — 200+ beds dedicated to advanced pediatric, gynecological and obstetric quaternary care; capex ~₹120 Cr (₹55 lakhs/bed); expected operational in 18–22 months after clearances; aimed at becoming nodal referral centre for Haryana/NCR.
- International patient business resilient at 27% of revenue despite West Asian war; no single regional dependency; management adds 2–3 new international markets each year; Q2 FY27 international share expected ~30%.
- VIMHANS project on track; deposit payments progressing — ₹130 Cr already paid, remaining ~₹120 Cr to be funded via existing IFC proceeds within FY27.
- Planned South Delhi facility under expansion pipeline; together with Raipur and Tower IV, total bed capacity target of ~2,000 operational beds by 2029–30.
- AI-enabled patient workflows, digital technologies and data analytics being expanded to improve patient flow and clinical decision-making.
- All-organ transplant programme (heart, lung) delivering excellent outcomes.
Analyst Q&A
Q. Outlook on international patient mix and drivers behind Q1 performance?
Despite West Asian war, international business contributed ~27% in Q1. We do not have single-region dependency; we add 2–3 new international markets annually. In Q2 we expect it to be closer to or better than 30%.
Q. Can you share revenue and EBITDA margins for Artemis Lite, Cardiac Care, and Daffodils?
Management declined to disclose centre-wise numbers on the call and asked the analyst to connect offline.
Q. Is Gurgaon hospital on track to reach 70% occupancy by Q2 FY27?
Yes, we are.
Q. Timeline for direct insurance empanelment at Raipur hospital?
We expect direct empanelment within 8–10 weeks. Meanwhile, an intermediary has been placed so that cashless TPA/insurance patient experience continues.
Q. What is the capex per bed for Gurgaon Tower IV and what will be the occupancy ramp-up?
Capex per bed is ~₹55 lakhs, total ~₹120 Cr. Tower IV should reach 50% utilization within first six months and break even in 8–10 months after commissioning.
Research and educational content only. Not investment advice.